Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.

This review covers cross-sex hormone therapy for gender dysphoria, noting improvements in psychological symptoms and quality of life but lacking definitive long-term safety data.